| CLASS | DRUG/TOX | LP7790-1 |
| COMPONENT | Vedolizumab | LP250843-2 |
| PROPERTY | MCnc | LP6827-2 |
| TIME_ASPCT | Pt | LP6960-1 |
| SYSTEM | Ser/Plas | LP7576-4 |
| SCALE_TYP | Qn | LP7753-9 |
| METHOD_TYP | IA | LP217197-5 |
| parent | Vedolizumab | Serum or Plasma | Drug toxicology | LP390600-7 |
| CLASSTYPE | Laboratory class | |
| ORDER_OBS | Both | |
| EXAMPLE_UNITS | ug/mL | |
| EXAMPLE_UCUM_UNITS | ug/mL |
| LONG_COMMON_NAME | en-US | Vedolizumab [Mass/volume] in Serum or Plasma by Immunoassay |
| LONG_COMMON_NAME | en-US | Vedolizumab [Mass/volume] in Serum or Plasma by Immunoassay |
| SHORTNAME | en-US | Vedolizumab SerPl IA-mCnc |
| ConsumerName | en-US | Vedolizumab, Blood |
| LONG_COMMON_NAME | fr-FR | Védolizumab [Masse/Volume] Sérum/Plasma ; Numérique ; Immunoanalyse |
| LONG_COMMON_NAME | es-MX | Vedolizumab: Suero o Plasma : Punto temporal: Concentración de masa: Cuantitativo: Inmunoensayo |
LOINC Version: 2.77
FHIR